| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
524348 Stock Overview
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally.
Aarti Drugs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹424.85 |
| 52 Week High | ₹669.30 |
| 52 Week Low | ₹378.40 |
| Beta | 1.18 |
| 1 Month Change | 5.82% |
| 3 Month Change | 2.99% |
| 1 Year Change | -34.70% |
| 3 Year Change | 266.92% |
| 5 Year Change | 230.85% |
| Change since IPO | 14,061.67% |
Recent News & Updates
Shareholder Returns
| 524348 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.3% | 0.5% | 1.0% |
| 1Y | -34.7% | -14.2% | 8.0% |
Return vs Industry: 524348 underperformed the Indian Pharmaceuticals industry which returned -14.2% over the past year.
Return vs Market: 524348 underperformed the Indian Market which returned 8% over the past year.
Price Volatility
| 524348 volatility | |
|---|---|
| 524348 Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: 524348 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 524348's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,450 | Prakash Patil | https://www.aartidrugs.co.in |
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer’s treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate, bisphenol – C, bisphenol – C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole.
Aarti Drugs Limited Fundamentals Summary
| 524348 fundamental statistics | |
|---|---|
| Market Cap | ₹39.34b |
| Earnings (TTM) | ₹1.91b |
| Revenue (TTM) | ₹25.31b |
20.6x
P/E Ratio1.6x
P/S RatioIs 524348 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524348 income statement (TTM) | |
|---|---|
| Revenue | ₹25.31b |
| Cost of Revenue | ₹17.35b |
| Gross Profit | ₹7.96b |
| Other Expenses | ₹6.05b |
| Earnings | ₹1.91b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 20.63 |
| Gross Margin | 31.45% |
| Net Profit Margin | 7.55% |
| Debt/Equity Ratio | 52.4% |
How did 524348 perform over the long term?
See historical performance and comparison